miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges

Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality in the world. Although considerable progress has been made in the diagnosis, treatment and prognosis of CVD, there is still a critical need for novel diagnostic biomarkers and new therapeutic interventions to decrease the incidence of this disease. Recently, there is increasing evidence that circulating miRNAs (miRNAs), i.e. endogenous, stable, single-stranded, short, non-coding RNAs, can be used as diagnostic biomarkers for CVD. Furthermore, miRNAs represent potential novel therapeutic targets for several cardiovascular disorders. In this review we provides an overview of the effects of several CVD; including heart failure, acute myocardial infarction, arrhythmias and pulmonary hypertension; on levels of circulating miRNAs. In addition, the use of miRNA as therapeutic targets is also discussed, as well as challenges and recommendations in their use in the diagnosis of CVD.

[1]  T. Thum,et al.  MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure , 2015, European journal of heart failure.

[2]  D. Catalucci,et al.  Reciprocal Regulation of MicroRNA-1 and Insulin-Like Growth Factor-1 Signal Transduction Cascade in Cardiac and Skeletal Muscle in Physiological and Pathological Conditions , 2009, Circulation.

[3]  S. Anker,et al.  Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. , 2013, International journal of cardiology.

[4]  Jian Chen,et al.  Expression profile analysis of circulating microRNAs and their effects on ion channels in Chinese atrial fibrillation patients. , 2015, International journal of clinical and experimental medicine.

[5]  Saumya Das,et al.  Circulating miR-30d Predicts Survival in Patients with Acute Heart Failure , 2017, Cellular Physiology and Biochemistry.

[6]  E. van Rooij,et al.  Inhibition of MicroRNA-92a Protects Against Ischemia/Reperfusion Injury in a Large-Animal Model , 2013, Circulation.

[7]  Michael J Pencina,et al.  Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus: The Framingham Heart Study , 2007, Circulation.

[8]  U. Frey,et al.  Decreased Expression of miR-133a but Not of miR-1 is Associated with Signs of Heart Failure in Patients Undergoing Coronary Bypass Surgery , 2013, Cardiology.

[9]  M. Tomaniak,et al.  Circulating microribonucleic acids miR-1, miR-21 and miR-208a in patients with symptomatic heart failure: Preliminary results. , 2015, Archives of cardiovascular diseases.

[10]  U. Laufs,et al.  Role of miR-21 in the pathogenesis of atrial fibrosis , 2012, Basic Research in Cardiology.

[11]  Kang Li,et al.  Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. , 2010, Biochemical and biophysical research communications.

[12]  M. Wood,et al.  Biomarker Potential of Extracellular miRNAs in Duchenne Muscular Dystrophy. , 2017, Trends in molecular medicine.

[13]  B. Bozdoğan,et al.  Circulating microRNAs in patients with ST-elevation myocardial infarction , 2015, Anatolian journal of cardiology.

[14]  Q. Kan,et al.  Regulation of microRNA-1 (miR-1) expression in human cancer. , 2017, Biochimica et biophysica acta. Gene regulatory mechanisms.

[15]  A. Tijsen,et al.  Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? , 2012, Circulation research.

[16]  S. Obad,et al.  Sex differences in response to miRNA‐34a therapy in mouse models of cardiac disease: identification of sex‐, disease‐ and treatment‐regulated miRNAs , 2016, The Journal of physiology.

[17]  M. Tendera,et al.  Circulating microRNAs (miR-423-5p, miR-208a and miR-1) in acute myocardial infarction and stable coronary heart disease. , 2013, Minerva cardioangiologica.

[18]  S. Girotra,et al.  Acute Coronary Syndrome , 2015, Journal of intensive care medicine.

[19]  A. Laucevičius,et al.  Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review , 2016, Cardiovascular research.

[20]  M. Mayr,et al.  MicroRNAs in Cardiovascular Disease. , 2016, Journal of the American College of Cardiology.

[21]  Jian-Fu Chen,et al.  The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation , 2006, Nature Genetics.

[22]  M. Tariq,et al.  The Role of MicroRNAs in Myocardial Infarction: From Molecular Mechanism to Clinical Application , 2017, International journal of molecular sciences.

[23]  Ye Tian,et al.  Plasma miR-1, miR-208, miR-499 as potential predictive biomarkers for acute myocardial infarction: An independent study of Han population , 2015, Experimental Gerontology.

[24]  X. Chen,et al.  Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases , 2008, Cell Research.

[25]  Federica Limana,et al.  Circulating microRNAs are new and sensitive biomarkers of myocardial infarction , 2010, European heart journal.

[26]  G. Takemura,et al.  Benefits of reperfusion beyond infarct size limitation. , 2009, Cardiovascular research.

[27]  C McRae,et al.  Myocardial infarction. , 2019, Australian family physician.

[28]  Da-Zhi Wang,et al.  MicroRNAs in cardiomyocyte development , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.

[29]  A. Darzi,et al.  Elevated serum microRNA 483-5p levels may predict patients at risk of post-operative atrial fibrillation , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[30]  B. C. Bernardo,et al.  miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart. , 2015, Future medicinal chemistry.

[31]  Jin Jen,et al.  Regulation of the SK3 channel by microRNA-499--potential role in atrial fibrillation. , 2013, Heart rhythm.

[32]  J. Bienertová-Vašků,et al.  Muscle-specific microRNAs in skeletal muscle development. , 2016, Developmental biology.

[33]  M F O'Rourke,et al.  Vascular impedance in studies of arterial and cardiac function. , 1982, Physiological reviews.

[34]  E. Meiri,et al.  Relation of reduced expression of MiR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure. , 2014, The American journal of cardiology.

[35]  W. Rottbauer,et al.  MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts , 2008, Nature.

[36]  A. Pasquinelli,et al.  Regulation by let-7 and lin-4 miRNAs Results in Target mRNA Degradation , 2005, Cell.

[37]  J. Lamb,et al.  The role of microRNAs in the idiopathic inflammatory myopathies , 2015, Current opinion in rheumatology.

[38]  S. Lowe,et al.  The microcosmos of cancer , 2012, Nature.

[39]  Y. Matsuki,et al.  Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells*♦ , 2010, The Journal of Biological Chemistry.

[40]  Claude Bouchard,et al.  Identification of heart rate-associated loci and their effects on cardiac conduction and rhythm disorders , 2014 .

[41]  E. Lianidou,et al.  Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability. , 2013, The Journal of molecular diagnostics : JMD.

[42]  C. Burge,et al.  Prediction of Mammalian MicroRNA Targets , 2003, Cell.

[43]  Y. Lo,et al.  Stability of endogenous and added RNA in blood specimens, serum, and plasma. , 2002, Clinical chemistry.

[44]  Jeffrey E. Thatcher,et al.  Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis , 2008, Proceedings of the National Academy of Sciences.

[45]  D. Mozaffarian,et al.  Executive summary: heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.

[46]  Yue Li,et al.  Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. , 2010, European heart journal.

[47]  S. Mowla,et al.  miRNA therapeutics in cardiovascular diseases: promises and problems , 2015, Front. Genet..

[48]  Jia Liu,et al.  The Protective Effect of MicroRNA-320 on Left Ventricular Remodeling after Myocardial Ischemia-Reperfusion Injury in the Rat Model , 2014, International journal of molecular sciences.

[49]  Jianhua Yao,et al.  Deregulated Cardiac Specific MicroRNAs in Postnatal Heart Growth , 2016, BioMed research international.

[50]  Jan A Staessen,et al.  Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease , 2010, Circulation. Cardiovascular genetics.

[51]  Yao Sun Myocardial repair/remodelling following infarction: roles of local factors. , 2008, Cardiovascular research.

[52]  M. Rodicio,et al.  Detection methods for microRNAs in clinic practice. , 2013, Clinical biochemistry.

[53]  Jian Shi,et al.  Overexpression of microRNA-99a attenuates heart remodelling and improves cardiac performance after myocardial infarction , 2014, Journal of cellular and molecular medicine.

[54]  T. Liu,et al.  Plasma microRNA-21 is a potential diagnostic biomarker of acute myocardial infarction. , 2016, European review for medical and pharmacological sciences.

[55]  M. Lohse,et al.  Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[56]  M. Małecki,et al.  Release kinetics of circulating miRNA-208a in the early phase of myocardial infarction. , 2015, Kardiologia polska.

[57]  Jagmeet P. Singh,et al.  Circulating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study , 2015, Circulation.

[58]  Ning Wang,et al.  MicroRNA-328 Contributes to Adverse Electrical Remodeling in Atrial Fibrillation , 2010, Circulation.

[59]  Offer Amir,et al.  Serum levels of microRNAs in patients with heart failure , 2012, European journal of heart failure.

[60]  M. Hirata,et al.  Analysis of Circulating miR‐1, miR‐23a, and miR‐26a in Atrial Fibrillation Patients Undergoing Coronary Bypass Artery Grafting Surgery , 2017, Annals of human genetics.

[61]  J. Bauersachs,et al.  Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. , 2011, Journal of molecular and cellular cardiology.

[62]  M. Ferracin,et al.  Quantification of Circulating miRNAs by Droplet Digital PCR: Comparison of EvaGreen- and TaqMan-Based Chemistries , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[63]  S. Shalaby,et al.  Serum miRNA‐499 and miRNA‐210: A potential role in early diagnosis of acute coronary syndrome , 2016, IUBMB life.

[64]  J. Sistino Epidemiology of cardiovascular disease in the last decade: treatment options and implications for perfusion in the 21st century , 2003, Perfusion.

[65]  T. Tuschl,et al.  Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers , 2014, Proceedings of the National Academy of Sciences.

[66]  C. Croce,et al.  MicroRNAs and Cancer: A Long Story for Short RNAs. , 2017, Advances in cancer research.

[67]  J. Pu,et al.  Circulating microRNAs are promising novel biomarkers of acute myocardial infarction. , 2011, Internal medicine.

[68]  Perry D Moerland,et al.  MiR423-5p As a Circulating Biomarker for Heart Failure , 2010, Circulation research.

[69]  M. Morishima,et al.  Atrial Fibrillation-Mediated Upregulation of miR-30d Regulates Myocardial Electrical Remodeling of the G-Protein-Gated K(+) Channel, IK.ACh. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[70]  Xueqi Li,et al.  Circulating MicroRNA-146a and MicroRNA-21 Predict Left Ventricular Remodeling after ST-Elevation Myocardial Infarction , 2015, Cardiology.

[71]  P. Doevendans,et al.  Role of apoptosis in reperfusion injury. , 2004, Cardiovascular research.

[72]  A. Karimpour-Fard,et al.  Micro-RNA expression in hypoplastic left heart syndrome. , 2015, Journal of cardiac failure.

[73]  L. Hood,et al.  Circulating microRNAs, potential biomarkers for drug-induced liver injury , 2009, Proceedings of the National Academy of Sciences.

[74]  Y. Kagaya,et al.  Left Ventricular Remodeling in Patients After Myocardial Infarction , 2005 .

[75]  T. Callis,et al.  MicroRNAs 1, 133, and 206: critical factors of skeletal and cardiac muscle development, function, and disease. , 2010, The international journal of biochemistry & cell biology.

[76]  Chaoqian Xu,et al.  MicroRNA-328 as a regulator of cardiac hypertrophy. , 2014, International journal of cardiology.

[77]  C. Bode,et al.  Chip-based digital PCR as a novel detection method for quantifying microRNAs in acute myocardial infarction patients , 2017, Acta Pharmacologica Sinica.

[78]  Chunxiang Zhang,et al.  A translational study of circulating cell-free microRNA-1 in acute myocardial infarction. , 2010, Clinical science.

[79]  Y. Pinto,et al.  Serially measured circulating microRNAs and adverse clinical outcomes in patients with acute heart failure , 2018, European journal of heart failure.

[80]  F. He,et al.  Circulating miR-208b and miR-34a Are Associated with Left Ventricular Remodeling after Acute Myocardial Infarction , 2014, International journal of molecular sciences.

[81]  J. Qian,et al.  miR-29 is a major regulator of genes associated with pulmonary fibrosis. , 2011, American journal of respiratory cell and molecular biology.

[82]  A. Rodríguez-Sinovas,et al.  Single Intracoronary Injection of Encapsulated Antagomir‐92a Promotes Angiogenesis and Prevents Adverse Infarct Remodeling , 2014, Journal of the American Heart Association.

[83]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[84]  K. Chowdhury,et al.  The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy , 2012, Nature Communications.

[85]  F. Atienza,et al.  miR-208b upregulation interferes with calcium handling in HL-1 atrial myocytes: Implications in human chronic atrial fibrillation. , 2016, Journal of molecular and cellular cardiology.

[86]  V. Harjola,et al.  Acute Heart Failure , 2018, Update in Intensive Care and Emergency Medicine.

[87]  E. Bocchi,et al.  The emerging role of miR-208a in the heart. , 2013, DNA and cell biology.

[88]  S. Nattel,et al.  MicroRNA29: A Mechanistic Contributor and Potential Biomarker in Atrial Fibrillation , 2013, Circulation.

[89]  A. Tijsen,et al.  Coronary Artery Disease CAD is caused by atherosclerosis of the coronary arteries , 2012 .

[90]  G. Paolisso,et al.  Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non‐responders , 2013, European journal of heart failure.

[91]  Bruce Henry Smaill,et al.  Structural Remodeling and Mechanical Function in Heart Failure , 2012, Microscopy and Microanalysis.

[92]  P. De Groote,et al.  Preclinical Development of a MicroRNA-Based Therapy for Elderly Patients With Myocardial Infarction. , 2016, Journal of the American College of Cardiology.

[93]  M. Zile,et al.  Relationship Between the Temporal Profile of Plasma microRNA and Left Ventricular Remodeling in Patients After Myocardial Infarction , 2011, Circulation. Cardiovascular genetics.

[94]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[95]  S. Arora,et al.  Exploiting Nanotechnology for the Development of MicroRNA-Based Cancer Therapeutics. , 2016, Journal of biomedical nanotechnology.

[96]  S. Kauppinen,et al.  Silencing of miR-34a Attenuates Cardiac Dysfunction in a Setting of Moderate, but Not Severe, Hypertrophic Cardiomyopathy , 2014, PloS one.

[97]  M. Mayr,et al.  Profiling of circulating microRNAs: from single biomarkers to re-wired networks , 2011, Cardiovascular research.

[98]  P. Kirchhof,et al.  Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. , 2011, Physiological reviews.

[99]  Naomi C. Chesler,et al.  Pulmonary vascular wall stiffness: An important contributor to the increased right ventricular afterload with pulmonary hypertension , 2011, Pulmonary circulation.

[100]  G. Ruvkun,et al.  Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans , 1993, Cell.

[101]  T. Yamaoka,et al.  MicroRNA 210 as a biomarker for congestive heart failure. , 2013, Biological & pharmaceutical bulletin.

[102]  S. Blankenberg,et al.  Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction. , 2015, World journal of cardiology.

[103]  J. Smith,et al.  Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction , 2013, BMC Cardiovascular Disorders.

[104]  Xiaobing Fu,et al.  Bottleneck limitations for microRNA-based therapeutics from bench to the bedside. , 2015, Pharmazie.

[105]  Guangwei Lv,et al.  MicroRNA-214 Inhibits Left Ventricular Remodeling in an Acute Myocardial Infarction Rat Model by Suppressing Cellular Apoptosis via the Phosphatase and Tensin Homolog (PTEN). , 2016, International heart journal.

[106]  Chaoqian Xu,et al.  MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection. , 2009, Cardiovascular research.

[107]  I. Komuro,et al.  Circulating p53-Responsive MicroRNAs Are Predictive Indicators of Heart Failure After Acute Myocardial Infarction , 2013, Circulation research.

[108]  Xiao-Ming Gao,et al.  Therapeutic silencing of miR‐652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[109]  T. Catela Ivković,et al.  microRNAs as cancer therapeutics: A step closer to clinical application. , 2017, Cancer letters.

[110]  Shengshou Hu,et al.  Plasma Levels of MicroRNA-499 Provide an Early Indication of Perioperative Myocardial Infarction in Coronary Artery Bypass Graft Patients , 2014, PloS one.

[111]  S. Blankenberg,et al.  Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. , 2018, European heart journal.

[112]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[113]  A. Zwinderman,et al.  Prognostic value of circulating microRNAs on heart failure‐related morbidity and mortality in two large diverse cohorts of general heart failure patients , 2018, European journal of heart failure.

[114]  S. Kauppinen,et al.  Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function , 2012, Proceedings of the National Academy of Sciences.

[115]  K. Abu-Amero,et al.  Utility of Circulating MicroRNAs as Clinical Biomarkers for Cardiovascular Diseases , 2015, BioMed research international.

[116]  E. Olson,et al.  Inhibition of miR-15 Protects Against Cardiac Ischemic Injury , 2012, Circulation research.

[117]  G. Steinbeck,et al.  Diagnostic and prognostic value of miR-1 and miR-29b on adverse ventricular remodeling after acute myocardial infarction - The SITAGRAMI-miR analysis. , 2017, International journal of cardiology.

[118]  A. Mebazaa,et al.  Circulating microRNAs and Outcome in Patients with Acute Heart Failure , 2015, PloS one.

[119]  P. Ponikowski,et al.  Signature of circulating microRNAs in patients with acute heart failure , 2016, European journal of heart failure.

[120]  Yanjie Lu,et al.  MicroRNA-101 Inhibited Postinfarct Cardiac Fibrosis and Improved Left Ventricular Compliance via the FBJ Osteosarcoma Oncogene/Transforming Growth Factor-&bgr;1 Pathway , 2012, Circulation.

[121]  B. Morris,et al.  Gene Expression Profiling Reveals Renin mRNA Overexpression in Human Hypertensive Kidneys and a Role for MicroRNAs , 2011, Hypertension.

[122]  A. Orekhov,et al.  Cardiac-specific miRNA in cardiogenesis, heart function, and cardiac pathology (with focus on myocardial infarction). , 2016, Journal of molecular and cellular cardiology.

[123]  Yan-jun Qin,et al.  MicroRNA 21 Inhibits Left Ventricular Remodeling in the Early Phase of Rat Model with Ischemia-reperfusion Injury by Suppressing Cell Apoptosis , 2012, International journal of medical sciences.